InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,907.86
(
0.99%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

wjlknew

Send PM Follow Ignore
Followers 1
Posts 219
Boards Moderated 0
Alias Born 03/09/2006

wjlknew

Re: jessellivermore post# 10927

Thursday, 05/15/2008 10:39:06 AM

Thursday, May 15, 2008 10:39:06 AM

Post# of 19309
jesse, I respect your opinions but ... in the interest of accuracy ...

The money GTC owes is not even pocket change for GE. Leo could probably walk away from ATryn and save money at this point. I suppose Merrimac is dependent for their product, but GTC does not provide product for LFB or Pharmathene (for Protexia). The LFB collaborations are all still pre-clinical and Pharmathene receives only consulting services from GTC. (Pharmathene has their own goat herd.)

Maybe Merrimac will pull GTC's chestnuts out of the fire.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up